Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05634967 · ClinicalTrials.gov registry record

Kesimpta (Ofatumumab) Pregnancy Registry

A clinical trial of Multiple Sclerosis and Pregnancy, sponsored by Novartis Pharmaceuticals.

Recruiting
Registry status
725
Enrollment target
1
Study location

NCT05634967: Recruiting study of Multiple Sclerosis and Pregnancy, sponsored by Novartis Pharmaceuticals.

NCT05634967 is a study of Multiple Sclerosis and Pregnancy that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 725 participants, above the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (24% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05634967, a study of Multiple Sclerosis and Pregnancy, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.

RECRUITING
Registry status
725 participants
Enrollment target
1
Study location

Study Summary

The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.

Primary Outcome

Number of participants with major structural defects will be collected

Conditions Studied

Multiple Sclerosis Pregnancy

Interventions

  • OTHER Kesimpta

Study Locations (1)

California

  • University of California San Diego OTIS - La Jolla

Trial Details

FieldValue
Enrollment Target 725 participants
Start Date 2023-01-05
Est. Completion 2033-02-28
Novartis Pharmaceuticals

1,375 total trials

What NCT05634967 shows while recruiting

NCT05634967 is an observational study that tracks outcomes without assigning an intervention. The registered 725 participants enrollment target is mid-sized for trials with a published cap, above the 583-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (24% higher).

The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Kesimpta is the first listed.

NCT05634967 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT05634967 about?

NCT05634967 is a clinical study titled "Kesimpta (Ofatumumab) Pregnancy Registry". The Kesimpta Pregnancy Registry is an observational, exposure cohort designed study to examine pregnancy and infant outcomes in women and infants who are exposed to Kesimpta (ofatumumab) during pregnancy to treat MS.

What is the current status of trial NCT05634967?

This trial is currently recruiting. The enrollment target is 725 participants. The study started on 2023-01-05. Estimated completion is 2033-02-28.

What conditions does trial NCT05634967 study?

This clinical trial studies the following conditions: Multiple Sclerosis, Pregnancy.

What interventions are being tested in trial NCT05634967?

The interventions under investigation include: Kesimpta (OTHER).

Who is sponsoring clinical trial NCT05634967?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05634967 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05634967's enrollment target sits among peer trials

725 38th of 315 higher than 278 of 315 other Multiple Sclerosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06731478 · 726 participants · Phase 3

    Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

  • NCT06664619 · 724 participants · Phase 3

    A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

  • NCT06641466 · 723 participants · Phase 3

    A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine

  • NCT07088068 · 723 participants · Phase 3

    A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT05634967

Source: ClinicalTrials.gov NCT05634967, the US trial registry maintained by the National Library of Medicine. NCT05634967 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.